Published in Invest Ophthalmol Vis Sci on July 01, 2002
Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci (2006) 1.52
TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest Ophthalmol Vis Sci (2011) 1.47
Müller cells as players in retinal degeneration and edema. Graefes Arch Clin Exp Ophthalmol (2007) 1.42
Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J Clin Invest (2008) 1.39
The effectiveness of vitrectomy for diffuse diabetic macular edema may depend on its preoperative optical coherence tomography pattern. Graefes Arch Clin Exp Ophthalmol (2016) 1.30
Preconditioning with endoplasmic reticulum stress mitigates retinal endothelial inflammation via activation of X-box binding protein 1. J Biol Chem (2010) 1.29
Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci U S A (2004) 1.26
NRF2 plays a protective role in diabetic retinopathy in mice. Diabetologia (2013) 1.06
Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. J Cell Physiol (2008) 1.06
TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage. J Neuroimmunol (2006) 1.04
Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. J Ophthalmol (2011) 1.02
Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability. PLoS One (2011) 1.00
Role of the retinal vascular endothelial cell in ocular disease. Prog Retin Eye Res (2012) 0.99
MEF2C ablation in endothelial cells reduces retinal vessel loss and suppresses pathologic retinal neovascularization in oxygen-induced retinopathy. Am J Pathol (2012) 0.98
Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye. PLoS One (2011) 0.95
A role for tumor necrosis factor-alpha in experimental Bacillus cereus endophthalmitis pathogenesis. Invest Ophthalmol Vis Sci (2008) 0.92
Increased intraocular insulin-like growth factor-I triggers blood-retinal barrier breakdown. J Biol Chem (2009) 0.90
Vascular endothelial growth factor-B gene transfer exacerbates retinal and choroidal neovascularization and vasopermeability without promoting inflammation. Mol Vis (2011) 0.89
Reduced retinal neovascularization, vascular permeability, and apoptosis in ischemic retinopathy in the absence of prolyl hydroxylase-1 due to the prevention of hyperoxia-induced vascular obliteration. Invest Ophthalmol Vis Sci (2011) 0.86
Emerging pharmacotherapies for diabetic macular edema. Exp Diabetes Res (2012) 0.86
Diabetic macular edema: New promising therapies. World J Diabetes (2013) 0.85
The effect of thalidomide on vascular endothelial growth factor and tumor necrosis factor-alpha levels in retinal ischemia/reperfusion injury. Graefes Arch Clin Exp Ophthalmol (2007) 0.84
Effects of intravitreal triamcinolone acetonide on retinal gene expression in a rat model of central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol (2011) 0.83
Effects of arteriolar constriction on retinal gene expression and Müller cell responses in a rat model of branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol (2013) 0.82
Anti-tumor necrosis factor alpha for retinal diseases: current knowledge and future concepts. J Ophthalmic Vis Res (2012) 0.81
Vitreous mediators in retinal hypoxic diseases. Mediators Inflamm (2013) 0.79
Topical pazopanib blocks VEGF-induced vascular leakage and neovascularization in the mouse retina but is ineffective in the rabbit. Invest Ophthalmol Vis Sci (2013) 0.78
Antiviral macrophage responses in flavivirus encephalitis. Indian J Med Res (2013) 0.78
The role of inflammation in the pathogenesis of macular edema secondary to retinal vascular diseases. Mediators Inflamm (2014) 0.77
Protocol: Effect of intravitreal bevacizumab (avastin) in the treatment of macular edema: A systematic review of randomized controlled trials. J Res Med Sci (2012) 0.76
Nrf2 in ischemic neurons promotes retinal vascular regeneration through regulation of semaphorin 6A. Proc Natl Acad Sci U S A (2015) 0.75
Role of agonistic autoantibodies against type-1 angiotensin II receptor in the pathogenesis of retinopathy in preeclampsia. Sci Rep (2016) 0.75
[TNFalpha inhibitors in the treatment of uveitis]. Ophthalmologe (2005) 0.75
Infliximab exerts a dose-dependent effect on retinal safety in the albino rabbit. Doc Ophthalmol (2017) 0.75
Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell (2002) 6.41
Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology (2010) 4.60
Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci U S A (2010) 4.30
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology (2010) 3.49
Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res (2003) 3.34
Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology (2009) 2.77
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology (2011) 2.65
Antioxidants reduce cone cell death in a model of retinitis pigmentosa. Proc Natl Acad Sci U S A (2006) 2.57
Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol (2006) 2.50
Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology (2012) 2.36
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell (2010) 2.26
Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci (2002) 2.03
Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa. J Cell Physiol (2007) 2.00
MicroRNAs regulate ocular neovascularization. Mol Ther (2008) 1.89
Oxidative damage is a potential cause of cone cell death in retinitis pigmentosa. J Cell Physiol (2005) 1.73
VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol (2003) 1.71
Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment. Am J Pathol (2002) 1.59
AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci (2002) 1.58
Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol (2013) 1.55
Angiopoietin-2 plays an important role in retinal angiogenesis. J Cell Physiol (2002) 1.50
The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization. FASEB J (2007) 1.49
TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest Ophthalmol Vis Sci (2011) 1.47
Intraoperative ketorolac and eye pain after viteoretinal surgery: a prospective, randomized, placebo-controlled study. Retina (2003) 1.46
Increased expression of brain-derived neurotrophic factor preserves retinal function and slows cell death from rhodopsin mutation or oxidative damage. J Neurosci (2003) 1.44
Genome-wide association study identifies two susceptibility loci for exudative age-related macular degeneration in the Japanese population. Nat Genet (2011) 1.43
Analysis of the VMD2 promoter and implication of E-box binding factors in its regulation. J Biol Chem (2004) 1.41
In vivo immunostaining demonstrates macrophages associate with growing and regressing vessels. Invest Ophthalmol Vis Sci (2007) 1.40
Increased expression of catalase and superoxide dismutase 2 reduces cone cell death in retinitis pigmentosa. Mol Ther (2009) 1.37
Comparison between retinal thickness analyzer and optical coherence tomography for assessment of foveal thickness in eyes with macular disease. Am J Ophthalmol (2002) 1.36
Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization. FASEB J (2006) 1.35
Oxidative stress modulates complement factor H expression in retinal pigmented epithelial cells by acetylation of FOXO3. J Biol Chem (2007) 1.34
Identification of gene expression changes associated with the progression of retinal degeneration in the rd1 mouse. Invest Ophthalmol Vis Sci (2004) 1.33
Effects of different types of oxidative stress in RPE cells. J Cell Physiol (2006) 1.32
NADPH oxidase plays a central role in cone cell death in retinitis pigmentosa. J Neurochem (2009) 1.32
Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization. FASEB J (2010) 1.31
A functional variant in the CFI gene confers a high risk of age-related macular degeneration. Nat Genet (2013) 1.29
Oxidative stress promotes ocular neovascularization. J Cell Physiol (2009) 1.28
Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol (2006) 1.28
Superoxide dismutase 1 protects retinal cells from oxidative damage. J Cell Physiol (2006) 1.27
Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. Am J Ophthalmol (2004) 1.26
Combined phacoemulsification, intraocular lens implantation, and vitrectomy for eyes with coexisting cataract and vitreoretinal pathology. Am J Ophthalmol (2003) 1.26
A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology (2006) 1.23
Supplemental oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci (2004) 1.20
Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization. J Cell Physiol (2004) 1.19
Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem Biophys Res Commun (2005) 1.19
Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology (2013) 1.17
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci (2010) 1.17
Retinal degeneration from oxidative damage. Free Radic Biol Med (2005) 1.17
Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci (2003) 1.16
Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci (2002) 1.16
Increased expression of glutathione peroxidase 4 strongly protects retina from oxidative damage. Antioxid Redox Signal (2009) 1.15
Overexpression of SOD in retina: need for increase in H2O2-detoxifying enzyme in same cellular compartment. Free Radic Biol Med (2011) 1.14
A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology (2009) 1.13
Endothelial nitric oxide synthase gene is associated with diabetic macular edema in type 2 diabetes. Diabetes Care (2004) 1.12
Gene expression variation in the adult human retina. Hum Mol Genet (2003) 1.12
Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive. FASEB J (2005) 1.12
Identification of novel genes preferentially expressed in the retina using a custom human retina cDNA microarray. Invest Ophthalmol Vis Sci (2003) 1.11
ADAM9 is involved in pathological retinal neovascularization. Mol Cell Biol (2009) 1.09
Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. J Cell Physiol (2003) 1.08
Mecamylamine suppresses Basal and nicotine-stimulated choroidal neovascularization. Invest Ophthalmol Vis Sci (2008) 1.06
Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. J Cell Physiol (2008) 1.06
Blockade of neuronal nitric oxide synthase reduces cone cell death in a model of retinitis pigmentosa. Free Radic Biol Med (2008) 1.06
High glucose-induced altered basement membrane composition and structure increases trans-endothelial permeability: implications for diabetic retinopathy. Curr Eye Res (2011) 1.05
Ocular gene transfer with self-complementary AAV vectors. Invest Ophthalmol Vis Sci (2007) 1.04
TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage. J Neuroimmunol (2006) 1.04
Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol (2008) 1.04
Retina-specific expression of PDGF-B versus PDGF-A: vascular versus nonvascular proliferative retinopathy. Invest Ophthalmol Vis Sci (2002) 1.04
In vivo micropathology of Best macular dystrophy with optical coherence tomography. Exp Eye Res (2003) 1.04
Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. Ophthalmology (2009) 1.03
Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist. Mol Pharmacol (2006) 1.03
Nitric oxide is proangiogenic in the retina and choroid. J Cell Physiol (2002) 1.03
Retinal neuroprotection against ischemic injury mediated by intraocular gene transfer of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci (2003) 1.03
Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. J Cell Physiol (2004) 1.02
Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration. Ophthalmology (2010) 1.01
Optical coherence tomography of peripheral retinal lesions in enucleated human eye specimens with histologic correlation. Am J Ophthalmol (2006) 1.01
VEGF receptor blockade markedly reduces retinal microglia/macrophage infiltration into laser-induced CNV. PLoS One (2013) 1.01
The iron carrier transferrin is upregulated in retinas from patients with age-related macular degeneration. Invest Ophthalmol Vis Sci (2006) 1.00
Injury-independent induction of reactive gliosis in retina by loss of function of the LIM homeodomain transcription factor Lhx2. Proc Natl Acad Sci U S A (2012) 1.00
Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability. PLoS One (2011) 1.00
Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. J Clin Invest (2014) 0.99
N-Acetylcysteine promotes long-term survival of cones in a model of retinitis pigmentosa. J Cell Physiol (2011) 0.99
Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol (2009) 0.98
CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration. J Ocul Biol Dis Infor (2010) 0.98
Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum Gene Ther (2003) 0.97
Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization. J Cell Physiol (2009) 0.97
Intraocular injection of an aptamer that binds PDGF-B: a potential treatment for proliferative retinopathies. J Cell Physiol (2006) 0.96
VMD2 promoter requires two proximal E-box sites for its activity in vivo and is regulated by the MITF-TFE family. J Biol Chem (2006) 0.96
Dynamic and quantitative analysis of choroidal neovascularization by fluorescein angiography. Invest Ophthalmol Vis Sci (2006) 0.96
Impact of optical coherence tomography on surgical decision making for epiretinal membranes and vitreomacular traction. Retina (2007) 0.96